Silence Therapeutics Appoints Dr Steven Romano as Incoming Chief Medical Officer and Head of Research and Development streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Dr. Romano will succeed Dr. Giles Campion, CMO and Head of R&D, following his retirement by year-end Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), an experienced and innovative
Operator: Good day and thank you for standing by. Welcome to the Silence Therapeutics 2022 Annual Results Conference Call and Webcast. Please be advised that today s conference is being recorded.
Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment
SLN360 reduced Lp(a) a key genetic risk factor for heart disease by up to 98% with reductions of up to 81% persisting at 150 days Results were simultaneously published in The Journal of the American